Once-monthly paliperidone palmitate versus oral antipsychotics in community-dwelling patients with schizophrenia: a multicenter real-world cohort study
10.11886/scjsws20260522001
- VernacularTitle:棕榈酸帕利哌酮注射液1个月剂型与口服抗精神病药治疗社区精神分裂症患者的多中心真实世界队列研究
- Author:
Xiuli XIE
1
;
Xun KANG
1
;
Rui LIU
1
;
Fangcheng FAN
1
;
Yajun SUN
2
;
Chang CHEN
3
;
Zhentao LIANG
1
;
Xueping LIN
1
Author Information
1. The Third People's Hospital of Foshan, Foshan Mental Health Center, Foshan 528041, China
2. The Third People's Hospital of Zhuhai, Zhuhai Center for Chronic Disease Prevention and Control, Zhuhai 519000, China
3. Shenzhen Kangning Hospital, Shenzhen 518020, China
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Once-monthly paliperidone palmitate;
Long-acting injectable antipsychotics;
Community mental health services;
Treatment satisfaction
- From:
Sichuan Mental Health
2026;39(5):421-429
- CountryChina
- Language:Chinese
-
Abstract:
BackgroundThe management of patients with schizophrenia in the community is an important component of public health and public safety. Poor adherence to oral antipsychotics and associated risk of relapse pose challenges to community-based schizophrenia care. The once-monthly paliperidone palmitate (PP1M) has theoretical advantages in improving treatment continuity. However, multicenter prospective evidence on its clinical outcomes and treatment satisfaction in real-world community settings remains limited. ObjectiveTo compare symptom outcomes, adverse reactions, and treatment satisfaction between PP1M and oral antipsychotics in community-dwelling patients with schizophrenia, with the aim of providing an evidence base for optimizing the management of patients with schizophrenia in the community. MethodsPatients with schizophrenia who were registered for community-based management in Foshan, Shenzhen, and Zhuhai, Guangdong Province, from April 2023 to October 2024 and who met the diagnostic criteria of the International Classification of Diseases, tenth edition (ICD-10) were enrolled. Among them, 86 patients received PP1M treatment (long-acting injectable group) and 164 received oral antipsychotics (oral medication group). The Positive and Negative Syndrome Scale (PANSS), the adverse drug reaction record form, and the Treatment Satisfaction Questionnaire for Medication-Second Edition (TSQM-II) were administered at baseline and at 3, 6, 9, and 12 months after enrollment. Repeated-measures analysis of variance was used to compare PANSS total scores, generalized estimating equations were used to compare adverse reaction counts, and linear mixed models were used to compare the overall satisfaction domain scores of the TSQM-II. Propensity score matching (PSM) was performed using 1∶1 nearest-neighbor matching, and sensitivity analysis was conducted. ResultsDuring follow-up, 19 patients in the long-acting injectable group and 16 in the oral medication group did not complete follow-up, leaving a final effective sample of 215 patients. Before PSM, PANSS total scores decreased over time in both groups, with a statistically significant time effect (F=4.216, P<0.05), whereas the group effect and group-by-time interaction effect were not statistically significant (P>0.05). At 3 months of enrollment, the time effect and group-by-time interaction effect for the adverse reaction counts were statistically significant in both groups (B=0.597, -0.497, P<0.05 or 0.01). The group effect (F=5.215, P=0.023) and time effect (F=2.584, P=0.036) for the overall satisfaction domain scores of the TSQM-II were statistically significant. After PSM, the pattern of findings for PANSS total scores and adverse reaction counts was maintained. ConclusionFor patients with schizophrenia in the community, PP1M and oral antipsychotics showed comparable symptom improvement over 12 months. The adverse reactions of PP1M were mainly concentrated in the early treatment period and then tended to stabilize,in addition, patients may be more satisfied with PP1M treatment. [Funded by 2024 Medical Research Project of Foshan City (number, 20240455)]